Platelet inhibition with cangrelor in patients undergoing PCI

The New England Journal of Medicine
Robert A HarringtonDeepak L Bhatt

Abstract

Cangrelor, a nonthienopyridine adenosine triphosphate analogue, is an intravenous blocker of the adenosine diphosphate receptor P2Y(12). This agent might have a role in the treatment of patients who require rapid, predictable, and profound but reversible platelet inhibition. We performed a large-scale international trial comparing cangrelor with 600 mg of oral clopidogrel administered before percutaneous coronary intervention (PCI) in patients with acute coronary syndromes. The primary efficacy end point was a composite of death from any cause, myocardial infarction, or ischemia-driven revascularization at 48 hours. We enrolled 8877 patients, and 8716 underwent PCI. At 48 hours, cangrelor was not superior to clopidogrel with respect to the primary composite end point, which occurred in 7.5% of patients in the cangrelor group and 7.1% of patients in the clopidogrel group (odds ratio, 1.05; 95% confidence interval [CI], 0.88 to 1.24; P=0.59). Likewise, cangrelor was not superior at 30 days. The rate of major bleeding (according to Acute Catheterization and Urgent Intervention Triage Strategy criteria) was higher with cangrelor, a difference that approached statistical significance (3.6% vs. 2.9%; odds ratio, 1.26; 95% CI, 0.99 to...Continue Reading

References

Jul 12, 1979·The New England Journal of Medicine·A R GrüntzigW E Siegenthaler
Sep 2, 1993·The New England Journal of Medicine·UNKNOWN GUSTO investigators
Jan 6, 2001·Lancet·UNKNOWN ESPRIT Investigators. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy
Aug 25, 2001·The New England Journal of Medicine·S YusufUNKNOWN Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators
Aug 25, 2001·Lancet·S R MehtaUNKNOWN Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators
Mar 11, 2005·The New England Journal of Medicine·Marc S SabatineUNKNOWN CLARITY-TIMI 28 Investigators
Nov 8, 2005·Lancet·Z M ChenUNKNOWN COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group
Jul 1, 2006·Nature Clinical Practice. Cardiovascular Medicine·Paul A Gurbel, Udaya S Tantry
Nov 25, 2006·The New England Journal of Medicine·Gregg W StoneUNKNOWN ACUITY Investigators
Feb 14, 2007·The New England Journal of Medicine·William H Maisel
May 2, 2007·Circulation·Donald E CutlipUNKNOWN Academic Research Consortium
Oct 24, 2007·Circulation·Kristian ThygesenNawwar Al-Attar
Oct 30, 2007·Circulation·Stephan Windecker, Bernhard Meier
Nov 6, 2007·The New England Journal of Medicine·Stephen D WiviottUNKNOWN TRITON-TIMI 38 Investigators
Dec 25, 2008·The New England Journal of Medicine·Jessica L MegaMarc S Sabatine
Feb 4, 2009·Circulation·Cyrus MehtaJames H Ware
Sep 1, 2009·The New England Journal of Medicine·Lars WallentinMona Thorsén

❮ Previous
Next ❯

Citations

Jan 19, 2012·JAMA : the Journal of the American Medical Association·Dominick J AngiolilloUNKNOWN BRIDGE Investigators
May 15, 2010·Journal of Thrombosis and Thrombolysis·Martin Moser, Christoph Bode
Jun 28, 2011·Journal of Thrombosis and Thrombolysis·Aldona KubicaAleksander Goch
Nov 28, 2012·Journal of Thrombosis and Thrombolysis·José L FerreiroDominick J Angiolillo
Jun 29, 2011·Purinergic Signalling·Stephen O'ConnorJean-Philippe Collet
Feb 24, 2010·Internal and Emergency Medicine·Marco Cattaneo, Gian Marco Podda
Nov 22, 2011·Current Atherosclerosis Reports·Luke KimDmitriy N Feldman
Sep 16, 2010·Current Treatment Options in Cardiovascular Medicine·Marc Bonaca, Robert P Giugliano
Oct 12, 2012·International Journal of Hematology·Fatemeh Moheimani, Denise E Jackson
Feb 14, 2013·Journal of Cardiovascular Translational Research·Fabiana RolliniDominick J Angiolillo
Apr 25, 2013·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Dominick J Angiolillo, José Luis Ferreiro
Jul 4, 2013·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Amitabh Prakash
Mar 20, 2010·The New England Journal of Medicine·Neil Ruparelia, Nicos Spyrou
Nov 17, 2009·The New England Journal of Medicine·Adnan Kastrati, Gjin Ndrepepa
Mar 12, 2013·The New England Journal of Medicine·Richard A Lange, L David Hillis
Sep 8, 2010·The New England Journal of Medicine·Shamir R MehtaSalim Yusuf
Mar 12, 2013·The New England Journal of Medicine·Deepak L BhattUNKNOWN CHAMPION PHOENIX Investigators
Mar 15, 2011·The American Journal of Bioethics : AJOB·Edward L Korn, Boris Freidlin
Dec 18, 2013·British Journal of Anaesthesia·A D Oprea, W M Popescu
Apr 12, 2011·Thrombosis and Haemostasis·Robert F Storey
Jan 5, 2013·Circulation Research·Desmond J Fitzgerald, Garret A Fitzgerald
Dec 14, 2011·Hematology·Alan D Michelson
Mar 4, 2010·Circulation Journal : Official Journal of the Japanese Circulation Society·Dominick J AngiolilloShinya Goto
Sep 22, 2010·Drug Design, Development and Therapy·Son V PhamPhuong-Anh T Pham
Jul 14, 2012·Journal of Blood Medicine·Jennifer Yeung, Michael Holinstat
Jul 27, 2010·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·David Vivas, Dominick J Angiolillo
Oct 13, 2012·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Saihari Sadanandan, Inder M Singh
Jul 9, 2010·Future Cardiology·Masafumi UenoDominick J Angiolillo
Jun 2, 2011·Future Cardiology·Stefan Lischke, David J Schneider
Apr 24, 2012·EuroIntervention : Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·Tarek A N AhmedWouter Jukema

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

The New England Journal of Medicine
Deepak L BhattCHAMPION PLATFORM Investigators
The New England Journal of Medicine
Lars WallentinMona Thorsén
Expert Review of Cardiovascular Therapy
José Luis FerreiroDominick J Angiolillo
The New England Journal of Medicine
Stephen D WiviottTRITON-TIMI 38 Investigators
© 2022 Meta ULC. All rights reserved